Patent Application
20170128462
Field of the Invention
The present invention relates to methods for treating female sexual dysfunction. In particular, the present invention relates to methods for treating a postmenopausal woman having hypoactive sexual desire disorder (HSDD) by administering to the woman a formulation comprising a therapeutically effective amount of an androgen that reduces the number of cardiovascular events in the woman.
Background of the Technology
HSDD is a condition in women that is associated with low serum testosterone. The American Psychiatric Association defines HSDD as the persistent or recurrent deficiency (or absence) of sexual fantasies and desire for sexual activity, which causes distress or interpersonal difficulty (American Psychiatric Association. and American Psychiatric Association. Task Force on DSM-IV., Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. 2000, Washington, D.C.: American Psychiatric Association. xxxvii, 943 p.).
When serum testosterone is decreased in women a number of changes may be observed: decreased overall energy, fatigue, blunted motivation, flattened mood, a decrease in the sense of well-being and an increased chance for depression. Lowered testosterone also may result in decreased sexual drive including fewer sexual thoughts and fantasies and also a decrease in aspects of sexual arousal including vaginal lubrication see, e.g., Gelfand, M. M. Am J Obstet Gynecol. 1999; 180(3 Pt 2):S325-7; Overlie, I., et al. Acta Obstet Gynecol Scand. 1999; 78(7):642-7; Guay, A. Medical aspects of Human Sexuality. 2001:32-38; and Rannevik, G., et al. Maturitas. 1986; 8(4):297-307.
In the United States, no FDA-approved testosterone therapies are available for the treatment of HSDD in women although in 2009, according to IMS data and independent market research more than 4 million testosterone prescriptions were written off-label for women. One goal of the testosterone therapy in postmenopausal women is to increase serum testosterone to the level of a younger woman in an effort to alleviate symptoms of HSDD. The unapproved testosterone formulations currently used to treat women have additional disadvantages. Proper administration, dosing, and daily compliance are a concern when using products for unapproved uses. For example, there is no quality control in the compounding pharmacy. Oral testosterone therapy uses modified testosterone analogues such as methyltestosterone and these molecules can result in elevated liver enzymes and conjugated bilirubin. Oralandrogens have been associated with hepatic neoplasms including hepatocellular carcinoma. Intramuscular testosterone treatment has been associated with mood swings because of wide peak-to-trough variations in plasma testosterone during the inter-injection period.
In addition to these disadvantages, concern exists about the potential cardiovascular risk in women who may use testosterone therapy for any use, especially since the removal from the market of VIOXX in 2004 and the elevated CV risk amongst estrogen/progestin users seen in the Women's Health Initiative. This concern has grown within the U.S. Food and Drug Administration (FDA) as well as prescribing practitioners in view of the increasing off-label use of testosterone in women.
To date the effect of androgens on cardiovascular events in postmenopausal women has not been investigated with the scientific rigor required to resolve this issue including the need for a sufficient duration of exposure or a sufficiently large study population. However the results of a late stage, randomized clinical trial of a precise dose of a topical testosterone formulation to postmenopausal women with HSDD significantly reduced the number of cardiovascular events compared to the expected number of cardiovascular events for an untreated postmenopausal woman.
Therefore, the formulations and methods of the present invention may be used to treat HSDD while also decreasing the risk that a postmenopausal woman will have a cardiovascular event.
In one aspect of the invention, a method for treating a woman having hypoactive sexual desire disorder (HSDD), comprising: administrating to the woman a topical formulation comprising a therapeutically effective amount of an androgen, whereby administering the formulation results in a reduction in cardiovascular events compared to a number of cardiovascular events expected for an untreated postmenopausal woman.
In certain aspects of the invention, the woman is surgically postmenopausal.
In other aspects of the invention, the woman is naturally postmenopausal.
In some embodiments, the androgen is selected from the group consisting of testosterone (17-β-hydroxyandrostenone), testosterone enanthate, testosterone propionate, testosterone decanoate, testosterone cypionate, methyl testosterone, testolactone, oxymetholone, fluoxymesterone and enanthate, propionate, cypionate, phenylacetate, acetate, isobutyrate, buciclate, heptanoate, decanoate, undecanoate, caprate and isocaprate esters of testosterone and 4-dihydrotestosterone. In a preferred embodiment, the androgen is testosterone, more preferably, present in an amount between about 0.50 mg to about 2.4 mg and even more preferably, between about 2.0 and 2.5 mg. In another preferred embodiment, the amount of testosterone in the formulation is 2.2 mg. In certain embodiments, the formulation may be delivered once per day.
In certain embodiments, the testosterone is administered in accordance with the methods conveniently in the form of a topical transdermal or transmucosal formulation, and the topical formulation may be provided in the form of a gel, lotion, cream, ointment, emulsion, or suspension.
In other embodiments, the topical formulation comprises at least one of a polyalcohol, alkanol, permeation enhancer, gelling agent, neutralizing agent, buffering agent, moisturizing agent, humectant, surfactant, antioxidant, emollient, or buffer.
In certain preferred embodiments, the topical formulation comprises an amount of testosterone between about 0.50 mg to about 2.4 mg, more preferably, 2.2 mg, and about 30% to about 98% ethanol or isopropanol; about 0.1% to about 5% isopropyl myristate or isopropyl palmitate; about 1% to about 5% sodium hydroxide; and about 0.1% to about 5% of a gelling agent (by weight of the formulation), or comprises about 50% to about 75% ethanol; about 0.5% to about 2% isopropyl myristate or isopropyl palmitate; about 1% to about 3% sodium hydroxide; about 0.5% to about 2% polyacrylic acid; and water in an amount sufficient to make the formulation 100% (by weight of the formulation).
In still other preferred embodiments, the testosterone formulation can further include an alkanol, for example, a C2 to C4 alcohol such as ethanol, isopropanol, and/or n-propanol, in an amount between about 5 to 80%; a polyalcohol such as polypropylene glycol in an amount between about 1% to 30%; and a permeation enhancer, such as diethylene glycol monomethyl ether or diethylene glycol monoethyl ether in an amount between about 1 to 30% by weight. The gel formulation in accordance with the invention facilitates the absorption of testosterone by the subject's dermal or mucosal surfaces, and minimizes the transfer or removal of the formulation from the user's skin after application.
The alkanol is provided in combination with water to form a hydroalcoholic mixture. Preferably, the alkanol comprises about 5% to 80% and the water comprises about 20% to 95% of the mixture by weight. The hydroalcoholic mixture may be present in an amount of about 40 to 98% by weight of the formulation.
In another preferred embodiment, the androgen, preferably testosterone, is present in an amount of about 0.50 mg to about 2.4 mg, more preferably, 2.2 mg, in a formulation containing: a fatty acid percutaneous absorption promoter in an amount of between 0.1% and 20% (w/w), preferably capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, palmitoleic acid, linoleic acid or linolenic acid, ethanol or isopropanol between 10% and 90% (w/w), and a stabilizer comprising the fatty acid ester of the fatty acid and the alcohol and present in an amount of between 0.1% and 10% (w/w), preferably ethyl oleate, isopropyl oleate, isopropyl myristate, isopropyl palmitate, ethyl octanoate, ethyl dodecanoate, ethyl linoleate or ethyl linolenate.
This formulation may further comprise between 0.5% and 20% of a polyalcohol (w/w), preferably glycerol, propylene glycol, polyethylene glycol, or mixtures thereof. The androgen formulation may further comprise between 0.2% and 30% (w/w) of a gelling agent. In preferred embodiments, the gelling agent is selected from carbomers, non-preneutralized acrylic polymers, cellulose derivatives, poloxamers, poloxamines, chitosan, dextran pectins, natural gums, and mixtures thereof. The formulation may also include a neutralizer. In preferred embodiments, the neutralizer is selected from triethanolamine, sodium hydroxide, ammonium hydroxide, potassium hydroxide, arginine, aminomethylpropanol and tromethamine, and mixtures thereof.
In other embodiments, the formulation comprises on a weight basis: (a) from about 1 to about 12% octyl salicylate; (b) from about 45 to about 90% of an alkanol selected from the group consisting of ethanol, isopropanol, and a mixture thereof; (c) from about 5 to about 45% water; and (d) from about 0.5 to about 5% of a gelling agent.
In still other embodiments, the formulation has pH of about 4 to about 8 and consists essentially of (i) permeation enhancer, preferably oleic acid; (ii) a C1 to C4 alkanol; and (iii) a polyalcohol; and iv) a gelling agent. In one embodiment, the alcohol is a member selected from the group consisting of ethanol, propanol, isopropanol and mixtures thereof, and is present from about 5% to about 65% weight to weight of the formulation, more preferably, 10% to about 40% weight to weight of said composition, and even more preferably, 25% to about 35% weight to weight of the formulation. In certain preferred embodiments, the polyalcohol is ethylene glycol, butylene glycol or propylene glycol, and the gelling agent is selected from Carbopol 1342, Carbopol 940, Klucel and Klucel HF, and is present at about 0.1% to about 10%.
In accordance with a further aspect of the invention, the testosterone formulations for use in the methods can be dispensed from a metered dosage device to provide convenience as well as precise metered dosages to users. Accordingly, the metered dosage device can be configured to dispense a precise amount of the testosterone formulation which corresponds to a desired and prescribed dosage of testosterone to the user.
The present invention relates to methods for treating female sexual dysfunction. In particular, the present invention relates to methods for treating a woman having HSDD, comprising: administering a transdermal formulation comprising a therapeutically effective amount of an androgen, whereby administering the formulation results in a reduction in number of cardiovascular events in the postmenopausal woman compared to an expected number of events for an untreated postmenopausal woman.
The invention is predicated, in part, upon the unexpected findings from a US-based, multi-center, randomized, placebo-controlled Phase 3 clinical trial, where the topical administration of a precise amount of testosterone in a topical formulation to postmenopausal women having HSDD significantly reduced the number of cardiovascular events compared to the expected number of cardiovascular events for an untreated postmenopausal woman. The findings indicate an unanticipated lower than expected cardiovascular event rate in postmenopausal woman using testosterone for the treatment of HSDD.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference.
As used herein, “ameliorate” means to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the androgen formulation.
As used herein, a “cardiovascular event” or “cardiovascular events” means one of the following occurrences: a cardiovascular death, a non-fatal stroke, a non-fatal myocardial infarction, hospitalized unstable angina (including acute coronary syndrome), angioplasty, coronary bypass surgery, a pulmonary embolism and deep vein thrombosis.
As used herein, “dose” and “dosage” mean a specific amount of an androgen for administration.
As used herein, “mucosa” means any moist anatomical membrane or surface on a mammal such as oral, buccal, vaginal, rectal, nasal or ophthalmic surfaces.
As used herein, “therapeutically effective amount” means a sufficient amount to provide the desired therapeutic effect.
As used herein, “therapeutically effective amount of an androgen” means a sufficient amount of an androgen to provide the desired therapeutic effect to ameliorate at least one symptom of HSDD.
As used herein, “topical formulation” means a formulation for transdermal or transmucosal administration i.e., delivery by passage of an androgen through the skin or mucosal tissue and into the bloodstream.
As used herein, “surgically postmenopausal woman” means a woman who has undergone bilateral oophorectomy.
As used herein, “naturally postmenopausal woman” means a woman who has not had a menstrual period for at least 12 months.
There are a number of androgens that are suitable for use in the methods disclosed herein. Examples of androgens which may be used in the present invention include testosterone (17-β-hydroxyandrostenone), and testosterone esters, such as testosterone enanthate, testosterone propionate, testosterone decanoate and testosterone cypionate. The aforementioned testosterone esters are commercially available or may be readily prepared using techniques known to those skilled in the art or described in the pertinent literature. Also, pharmaceutically acceptable esters of testosterone and 4-dihydrotestosterone, typically esters formed from the hydroxyl group present at the C-17 position (such as enanthate, propionate, cypionate, phenylacetate, acetate, isobutyrate, buciclate, heptanoate, decanoate, undecanoate, caprate and isocaprate esters); and pharmaceutically acceptable derivatives of testosterone such as methyl testosterone, testolactone, oxymetholone and fluoxymesterone may be used.
In preferred embodiments, the androgen is testosterone, preferably in an amount of 0.50 to 2.4 mg, and more preferably, 2.0 to 2.5 mg, or even still more preferred, the amount is 2.2 mg that is administered daily.
In certain embodiments, a therapeutically effective amount of an androgen is administered to a woman using a topical formulation, i.e., a transdermal or transmucosal application. A number of topical formulations for transdermal or transmucosal administration of androgens are suitable for use in the methods herein, and are well known to those of skill in the art (e.g., see U.S. Pat. Nos. 5,723,114; 5,906,830; 6,228,852; 6,319,913; 6,348,210; 6,503,894; 6,562,369; 6,562,370; 6,743,448; 6,818,226; 6,923,989; 7,018648; 7,157,097; 7,198,801; 7,438,203; and 7,611,727).
In general, the transdermal and transmucosal formulations comprise an androgen and delivery vehicle that facilitates penetration and absorption of the androgen. In particular, the formulation comprises an androgen; and a delivery vehicle, which may comprise an alkanol, a polyalcohol, and a permeation enhancer to provide permeation enhancement of the androgen through mammalian dermal or mucosal surfaces. The formulation may further comprise a gelling agent, neutralizing agent, buffering agent, moisturizing agent, humectant, surfactant, antioxidant, emollient, and/or buffer, and may be provided in the form of a gel, lotion, cream, ointment, emulsion, or suspension.
Polyalcohols.
In accordance with the invention, the polyalcohol may be advantageously present in an amount between about 1% and 30% by weight of the vehicle. The monoalkyl ether of diethylene glycol may be present in an amount of about 0.2% and 25% by weight of the vehicle and the alkanol may be present in an amount between about 5 to 75% by weight of the vehicle. Generally, the alkanol can be present in a hydroalcoholic mixture with water. In certain embodiments, the polyalcohol may be propylene glycol, butylene glycol, hexylene glycol, and ethylene glycol. In certain preferred embodiments, the polyalcohol is propylene glycol.
Alkanols.
The alkanol may be a C2 to C4 alcohol, such as ethanol, isopropanol, or n-propanol. In certain preferred embodiments, the alkanol is ethanol.
Permeation Enhancers.
In one embodiment, the permeation enhancer contains a saturate fatty alcohol or fatty acid given by the formula CH3—(CH2)n—CH2OH or CH3—(CH2)n—(CH)2 COOH respectively, in which n is an integer from 8 to 22, preferably 8 to 12, most preferably 10 or an unsaturated fatty alcohol or fatty acid given by the formula CH3—(CnH2(n-x))—OH or CH3—(CnH2(n-x))—COOH respectively in which n is an integer from 8 to 22. Instead or in addition to the saturated fatty alcohol and fatty acids, second component that is a monoalkyl ether of diethylene glycol. The permeation enhancer of monoalkyl ether of diethylene is, for example, diethylene glycol monoethyl ether or diethylene glycol monomethyl ether. In certain preferred embodiments, the permeation enhancer is diethylene glycol monoethyl ether.
In other embodiments, the permeation enhancer is one or more esters selected from the group consisting of a long chain alkyl para-aminobenzoate, long chain alkyl dimethyl-para-aminobenzoate, long chain alkyl cinnamate, long chain alkyl methoxycinnamate and long chain alkyl salicylate. In preferred embodiments, the permeation enhancer is one or more esters selected from the group consisting of C8 to C18 alkyl para-aminobenzoate, C8 to C18 alkyl dimethyl-para-aminobenzoate, C8 to C18 alkyl cinnamate, C8 to C18 alkyl methoxycinnamate and C8 to C18 alkyl salicylate.
In certain preferred embodiments, the permeation enhancer is oleic acid, octyl-salicylate, isopropyl palmitate or isopropyl myristate.
The selection of the permeation enhancer can affect the amount and rate of transdermal or transmucosal absorption of the present testosterone formulation. The amount of the permeation enhancer may be optimized. In one preferred embodiment, the permeation enhancer may comprise about 1 to 30% of the formulation by weight.
Gelling Agent.
In one aspect of the invention, the present formulation may further include a thickening agent or gelling agent present in an amount sufficient to alter the viscosity of the formulation. A gelling agent can be selected from the group including: carbomer, carboxyethylene or polyacrylic acid such as Carbopol 980 or 940 NF, 981 or 941 NF, 1382 or 1342 NF, 5984 or 934 NF, ETD 2020, 2050, 934P NF, 971P NF, 974P NF, Noveon AA-1 USP; cellulose derivatives such as ethylcellulose, hydroxypropylmethylcellulose (HPMC), ethylhydroxyethylcellulose (EHEC), carboxymethylcellulose (CMC), hydroxypropylcellulose (HPC) (Klucel different grades), hydroxyethylcellulose (HEC) (Natrosol grades), HPMCP 55, Methocel grades; natural gums such as arabic, xanthan, guar gums, alginates; polyvinylpyrrolidone derivatives such as Kollidon grades; and polyoxyethylene polyoxypropylene copolymers such as Lutrol F grades 68, 127. Other gelling agents may include chitosan, polyvinyl alcohols, pectins, and veegum grades.
In certain preferred embodiments, the gelling agent is Lutrol F grades and Carbopol grades. The gelling agent may be present from about 0.2 to about 30.0% w/w depending on the type of polymer. In other preferred embodiments, the gelling agent includes about 0.5%-5% by weight of a thickening agent. The amount of the gelling agent in the formulation may be selected to provide the desired product consistency and/or viscosity to facilitate application to the skin.
Preservatives.
The formulation may further include preservatives such as but not limited to benzalkonium chloride and derivatives, benzoic acid, benzyl alcohol and derivatives, bronopol, parabens, centrimide, chlorhexidine, cresol and derivatives, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric salts, thimerosal, sorbic acid and derivatives. The preservative may be present from about 0.01 to about 10.0% w/w of the formulation depending on the type of compound.
Antioxidants.
The formulation may optionally include antioxidants such as but not limited to tocopherol and derivatives, ascorbic acid and derivatives, butylated hydroxyanisole, butylated hydroxytoluene, fumaric acid, malic acid, propyl gallate, metabisulfates and derivatives. The antioxidant may be present from about 0.001 to about 5.0% w/w of the formulation depending on the type of compound.
Buffers.
The formulation may further include buffers such as carbonate buffers, citrate buffers, phosphate buffers, acetate buffers, hydrochloric acid, lactic acid, tartric acid, diethylamine, triethylamine, diisopropylamine, aminomethylamine. Although other buffers as known in the art may be included. The buffer may replace up to 100% of the water amount within the formulation.
Humectant.
The formulation may further include humectant, such as but not limited to glycerin, propylene, glycol, sorbitol, triacetin. The humectant may be present from about 1 to 10% w/w of the formulation depending on the type of compound.
Sequestering Agent.
The formulation may further include a sequestering agent such as edetic acid. The sequestering agent is present from about 0.001 to about 5% w/w of the formulation depending on the type of compound.
Surfactant.
The formulation may further include anionic, non-ionic or cationic surfactants. The surfactant may be present from about 0.1% to about 30% w/w depending on the type of compound.
pH Regulator.
Optionally, the formulation may include a pH regulator, generally, a neutralizing agent, which can optionally have crosslinking function. By way of example and not limitation, the pH regulator may include a ternary amine such as triethanolamine, tromethamine, tetrahydroxypropylethylendiamine, NaOH solution. The pH regulator may be present in the formulations in about 0.05 to about 2% w/w.
Moisturizers and Emollients.
Optionally, the formulation may include moisturizers and/or emollients to soften and smooth the skin or to hold and retain moisture. By way of example and not limitation, moisturizers and emollients may include cholesterol, lecithin, light mineral oil, petrolatum, and urea.
For any particular formulation, these other ingredients may be selected to achieve the desired drug delivery profile and the amount of penetration desired. The optimum pH may also be determined and may depend on, for example, the base and degree of flux required.
In one embodiment, the androgen, preferably testosterone, is present in an amount of about 0.50 mg to about 2.4 mg, more preferably, 2.2 mg, in a formulation containing: about 30% to about 98% ethanol or isopropanol; about 0.1% to about 5% isopropyl myristate or isopropyl palmitate; about 1% to about 5% sodium hydroxide; and about 0.1% to about 5% of a gelling agent (weight to weight). In another embodiment, the androgen, preferably testosterone, is present in an amount of about 0.50 mg to about 2.4 mg in a formulation containing: about 50% to about 75% ethanol; about 0.5% to about 2% isopropyl myristate or isopropyl palmitate; about 1% to about 3% sodium hydroxide; about 0.5% to about 2% polyacrylic acid; and water in an amount sufficient to make the formulation 100% (weight to weight).
In another preferred embodiment, the androgen formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids and long-chain fatty esters in order to avoid potential undesirable odor and irritation effects caused by such compounds during use of the formulation. Thus, advantageously, the formulations of the present invention do not include the undesirable odor-causing and irritation-causing permeation enhancers that were once thought to be necessary for such transdermal or transmucosal formulations.
In this embodiment, the androgen, preferably testosterone, is present in an amount of about 0.50 mg to about 2.4 mg, more preferably, 2.2 mg, in a formulation comprising: a C2 to C4 alkanol, a polyalcohol, and a permeation enhancer of monoalkyl ether of diethylene glycol present in an amount sufficient to provide permeation enhancement of the androgen through mammalian dermal or mucosal surfaces. In preferred embodiments, the alkanol is a C2 to C4 alcohol selected from the group consisting of ethanol, isopropanol, and n-propanol, the polyalcohol is polypropylene glycol, and the permeation enhancer includes diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, and mixtures thereof.
In preferred embodiments, the formulation comprises 1% testosterone; 47.5% ethanol; 6% propylene glycol; 5% diethylene glycol monoethyl ether; 1.2% Carbomer, Carbopol 980; 0.35% triethanolamine; 0.06% edetate disodium; and 38.89% water. The viscosity of the transdermal gel formulation was 22,000-25,000 cps (Range 16,000-40,000) having a slightly acidic pH, between 5 and 7.
In another embodiment, the androgen, preferably testosterone, is present in an amount of about 0.50 mg to about 2.4 mg, more preferably, 2.2 mg, in a formulation containing: a fatty acid percutaneous absorption promoter in an amount of between 0.1% and 20% (w/w), preferably capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, palmitoleic acid, linoleic acid or linolenic acid, ethanol or isopropanol between 10% and 90% (w/w), and a stabilizer comprising the fatty acid ester of the fatty acid and the alcohol and present in an amount of between 0.1% and 10% (w/w), preferably ethyl oleate, isopropyl oleate, isopropyl myristate, isopropyl palmitate, ethyl octanoate, ethyl dodecanoate, ethyl linoleate or ethyl linolenate.
This formulation may further comprise between 0.5% and 20% of a polyalcohol (w/w), preferably glycerol, propylene glycol, polyethylene glycol, or mixtures thereof. The androgen formulation may further comprise between 0.2% and 30% (w/w) of a gelling agent. In preferred embodiments, the gelling agent is selected from carbomers, non-preneutralized acrylic polymers, cellulose derivatives, poloxamers, poloxamines, chitosan, dextran pectins, natural gums, and mixtures thereof. The formulation may also include a neutralizer. In preferred embodiments, the neutralizer is selected from triethanolamine, sodium hydroxide, ammonium hydroxide, potassium hydroxide, arginine, aminomethylpropanol and tromethamine, and mixtures thereof.
In certain other formulations, the permeation enhancer may be selected from one or more esters of a long chain alkyl para-aminobenzoate, a long chain alkyl dimethyl-para-aminobenzoate, a long chain alkyl cinnamate, a long chain alkyl methoxycinnamate and a long chain alkyl salicylate. In preferred embodiments, the permeation enhancer is one or more esters selected from the group consisting of C8 to C18 alkyl para-aminobenzoate, C8 to C18 alkyl dimethyl-para-aminobenzoate, C8 to C18 alkyl cinnamate, C8 to C18 alkyl methoxycinnamate and C8 to C18 alkyl salicylate, and the formulation further comprises an alkanol selected from the group consisting of ethanol and isopropyl alcohol.
For certain embodiments, the formulation comprises on a weight basis: (a) from about 1 to about 12% octyl salicylate; (b) from about 45 to about 90% of an alkanol selected from the group consisting of ethanol, isopropanol, and a mixture thereof; (c) from about 5 to about 45% water; and (d) from about 0.5 to about 5% of a gelling agent.
In other embodiments, the formulation has pH of about 4 to about 8 and consists essentially of (i) permeation enhancer, preferably oleic acid; (ii) a C1 to C4 alkanol; and (iii) a polyalcohol; and iv) a gelling agent. In one embodiment, the alcohol is a member selected from the group consisting of ethanol, propanol, isopropanol and mixtures thereof, and is present from about 5% to about 65% weight to weight of the formulation, more preferably, 10% to about 40% weight to weight of said composition, and even more preferably, 25% to about 35% weight to weight of the formulation. In preferred embodiments, the polyalcohol is ethylene glycol, butylene glycol or propylene glycol, and the gelling agent is selected from Carbopol 1342, Carbopol 940, Klucel and Klucel HF, and is present at about 0.1% to about 10%.
Cardiovascular disease is the leading cause of death in women. Compared to men, premenopausal women are relatively protected from cardiovascular disease, but gradually lose this protection following menopause as estrogen and possibly androgen levels decline. Patterns in Coronary Heart Disease—Morbidity and Mortality in the Sexes: A 26-Year Follow-Up of the Framingham Population, Lerner & Kannel, Amer. Heart J., 111: 383-90 (1986). The onset of cardiovascular disease is hastened in women by prematurely induced surgical menopause and its attendant reduction in endogenous hormone levels. Time Interval from Castration in Premenopausal Women to Development of Excessive Coronary Atherosclerosis, Parrish, H. M. et al., Amer. J. Obst. Gynecol., 99: 155-62 (1967). Since a large majority of women having HSDD are postmenopausal, methods of treating HSDD must take into consideration the increasing risk of women to potential cardiovascular events when administering therapy for HSDD.
Following menopause, the rate of cardiovascular disease in women, such as hyperlipidemia, increases to match the rate seen in men. In the eighth and ninth decades, the incidence of deaths from ischemic heart disease, approaches that of men (Havlik, R. J. and Manning-Feinleid, P. H. 1979, NIH Publication No. 79-1610, U.S. Department of HEW). It has been reported in the literature that postmenopausal women undergoing estrogen therapy have a return of serum lipid levels to concentrations similar to those of the premenopausal state. Despite this normalization of serum lipids, estrogen does not translate to fewer cardiovascular events (Hsia, J., et al. Arch Intern Med. 2006; 166(3):357-65; Hodis, H. N. and Mack, W. J. Menopause. 2007). Indeed estrogen is not recommended as a cardio-protectant.
The formulations of the present invention address each of these issues by providing a therapeutically effective treatment for HSDD while also providing the reduction in the number of cardiovascular events in the treated woman.
The present invention, in part, provides methods of treating female sexual dysfunction using an androgen, preferably testosterone.
In one aspect of the invention, methods for treating a postmenopausal woman having HSDD comprising: administering a topical formulation comprising a therapeutically effective amount of an androgen, whereby administering the formulation results in a reduction in the risk of a cardiovascular event in the woman compared to the risk of a cardiovascular event in an untreated postmenopausal woman or compared to a population of postmenopausal women are provided.
In one embodiment, the effective amount of testosterone is provided in clear, water washable, cool to the touch, quick drying, spreadable and/or non-greasy formulations, such as a gel, or similar fluid formulations such as but not limited to a cream, lotion, ointment, or suspension, which can be applied directly to the skin. The present transdermal or transmucosal testosterone therapy provides important advantages over the known oral, intramuscular, and transdermal products by advantageously delivering serum testosterone concentrations that are not subject to first-pass metabolism and avoiding wide swings in serum testosterone concentrations while reducing skin reactions often observed with existing transdermal patch products.
The present formulation may be applied once daily, or multiple times per day depending upon the condition of the woman. The formulation of the invention may be applied topically to any body part, such as the thigh, abdomen, shoulder, and upper arm. In one embodiment, a formulation in the form of a gel is applied to about a 5 inch by 5 inch area of skin. Application may be to alternate areas of the body as applications alternate. For example, the gel may be applied to the thigh for the first application, the upper arm for the second application, and back to the thigh for the third application. This may be advantageous in alleviating any sensitivity of the skin to repeated exposure to components of the formulation.
The present invention, therefore, provides a method of providing testosterone therapy in a manner that is not only clinically effective but also user-friendly. Not only does the present method provide an effective dosage of testosterone, but it also enables easy administration and compliance by patients, since the present transdermal/transmucosal testosterone formulation is easy and painless to apply. Furthermore, as the present formulation is absorbed into the patient's skin or mucosa, it is “invisible” after application, and therefore much more discreet than the conventional patch products that have been used for transdermal testosterone delivery. Manufacturers will also appreciate that the present formulation is more cost-effective to produce as it does not require extra steps and materials, such as adhesives and fabrics which are required for production of traditional patch products. Accordingly, the present testosterone formulation and method provide numerous advantages over the existing testosterone therapy products both for the consumer and the manufacturer.
The amount of androgen and dosing schedules necessary to provide a therapeutically effective amount may be monitored by following serum concentrations of testosterone. Methods for measuring the serum levels of such hormones, particularly testosterone, are well known to one of ordinary skill in the art. The serum measures are preferably made when the therapeutically targeted level of steady state has been achieved.
In certain embodiments, the reduction in the observed number of cardiovascular events compared to the expected number of cardiovascular events is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% compared to the expected number of cardiovascular events for a postmenopausal woman or a population of postmenopausal women.
A metered dosage device for administration of the androgen formulation may be used in connection with the methods herein. Any metered dosage device capable of dispensing and administering an androgen in a gel or ointment form may be used (e.g., see U.S. Patent Application Publication No. US2006027064).
Preferably, the metered dosage device is capable of dispensing a predetermined, precise amount of transdermal testosterone formulation produced by the instant methods.
For example, when used in combination with a gel containing 1% testosterone, the present device may be designed to dispense 0.22 g of the transdermal formulation when activated e.g., by pressing on the pump, such that about 2 mg of testosterone is dispensed. Thus, the metered dosage device may be conveniently used for self-administration of a precise testosterone dosage. When smaller doses are to be applied more often, the device can be designed to dispense 1.0 or even 0.5 mg of testosterone upon each activation. Thus, four 0.5 mg doses, two 1 mg doses or a single 2 mg dose can be administered to provide the preferred amount of 2 mg of testosterone each day.
The following Examples are illustrative and are not meant to be limiting.
The following example calculates the expected number of cardiovascular events in a population of postmenopausal women derived from historical data. The estimate of the expected rate of cardiovascular events has been determined from the event rates noted in the Women's Health Initiative (WHI), a Department of Health and Human Services National Institute of Health-sponsored study of women between 50 and 79 years of age, a similar set of women between that age were enrolled for determining the actual number of cardiovascular events as described in Example 2.
Table 1a below is adapted from Table 2 of the Hsia et al (Hsia, J., et al. Arch Intern Med. 2006; 166(3):357-65.) report of the primary cardiovascular outcomes observed in the WHI and from the review of the WHI cardiovascular outcomes from Hodis and Mack. (Hodis, H. N. and Mack, W. J. Menopause. 2007) The rates in the table below represent the cardiovascular event rate by age group in the placebo-treated subjects in the combined estrogen/progestin arm of the WHI.
Subjects in the clinical trial described in Example 2 were at somewhat greater risk than those women who were part of the WHI. Rossouw et al describe the risk factors of WHI subjects as “levels of cardiovascular risk factors were consistent with a generally healthy population of postmenopausal women”. (Rossouw, J. E., Jama. 2002; 288(3):321-33.) The cardiovascular risk factors in the WHI population were reported by Rossouw et al as follows: baseline use of statins, 6.6%; current smokers, 10.5%; treated diabetics, 4.4%; aspirin use (≧80 mg/d), 19.1%; and hypertensive treatment or BP ≧140/90, 35.7%. Table 1b below shows the difference in overall cardiovascular event rates in subjects with and without risk factors in the WHI.
Overall, the cardiovascular event rate in women in the WHI study who had at least one cardiovascular risk factor was approximately 2-fold greater than in women without any cardiovascular risk factors. In estimating the cardiovascular event rate in this study, it is assumed that the quality of medical care will be slightly improved, overall, over the 10 years since the WHI subjects were enrolled. Thus, a conservative estimate of the relative increase in cardiovascular event rates compared to the overall WHI event rate is approximately 40% higher than that reported in the original publication (i.e., approximately 1.4-fold greater) (Table 1c).
The sample size used to determine the fraction of accrual in each age category in the proposed study was: 50-59, 50%; 60-69, 35%; 70-79, 15%.
The weighted average of cardiovascular events per 1,000 subjects followed on average for 12 months with the fractional accrual by age as described would be as shown in Table 1d below.
Based on an estimated rate of accrual between 150 and 300 subjects per month, the expected composite cardiovascular event rate is 2.0%.
The following example describes the results obtained from an experimental study of 3,656 postmenopausal women to determine the observed number of cardiovascular events in women having HSDD that have been administered a therapeutically effective amount of testosterone. Women between the age of 50 and 79 years were enrolled in this experimental study.
A randomized, double-blind, placebo-controlled, multi-center Phase 3 study of the long-term safety and efficacy of a preferred androgen formulation of the present invention in the treatment of HSDD in postmenopausal women was conducted. A total of 3,656 women were screened and enrolled in the Phase 3 trial based on predetermined eligibility criteria. Eligible postmenopausal women were at least 50 years of age, have increased risk for cardiovascular disease based on defined cardiovascular risk factors and have a clinical diagnosis of HSDD.
The study consisted of a screening period of up to 8 weeks and a 60-month treatment period. Eligible women were randomized in a 1:1 ratio to receive either a testosterone gel (0.22 g; 300 mcg/day) or an equivalent weight of placebo gel (0.22 g) daily. Adverse cardiovascular and breast cancer events (ABC events) were assessed at each subject contact in addition to the usual assessments of safety and concomitant medications. The primary safety outcome measure of the study was the combined incidence of a subject's first cardiovascular event that includes cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, hospitalized unstable angina, coronary revascularization, and venous thromboembolic events (pulmonary embolism and deep vein thromboses). The co-primary safety outcome measure was the rate of a subject's first invasive breast cancer. The secondary safety outcomes included specific cardiovascular morbidities including cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, hospitalized unstable angina, coronary revascularization, venous thromboembolic events, and all-cause mortality. An additional secondary safety outcome includes breast carcinoma in situ. Cardiovascular events occurring during the course of the study were adjudicated by the Cardiovascular Endpoints Committee. Breast cancer adverse events were reviewed by the Breast Endpoints Committee and include breast cancer and carcinoma in situ. In addition, all breast biopsy pathology reports were reviewed by the Breast Endpoints Committee.
There were twelve adjudicated cardiovascular events determined from this Phase 3 clinical trial after over 4,000 woman-years of therapy. A comparison of the observed number of cardiovascular events to the expected rate of cardiovascular events revealed that the number of observed events was only about 29% of those expected, resulting in a 71% reduction in cardiovascular events.
This application claims priority from U.S. Provisional Application Ser. No. 61/398,941, filed Jul. 2, 2010. The entirety of this provisional application is hereby incorporated by reference.
| Number | Date | Country | |
|---|---|---|---|
| 61398941 | Jul 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13135224 | Jun 2011 | US |
| Child | 15331360 | US |
